Pfizer Inc. (PFE) Shares Bought by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund boosted its holdings in Pfizer Inc. (NYSE:PFE) by 31.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,293,025 shares of the biopharmaceutical company’s stock after buying an additional 553,113 shares during the period. Pfizer accounts for approximately 1.6% of Oregon Public Employees Retirement Fund’s holdings, making the stock its 5th biggest position. Oregon Public Employees Retirement Fund’s holdings in Pfizer were worth $100,091,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. West Chester Capital Advisors Inc. raised its stake in shares of Pfizer by 10.4% in the third quarter. West Chester Capital Advisors Inc. now owns 13,079 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 1,234 shares in the last quarter. Spectrum Asset Management Inc. NB CA raised its stake in shares of Pfizer by 176.1% in the third quarter. Spectrum Asset Management Inc. NB CA now owns 50,276 shares of the biopharmaceutical company’s stock valued at $2,216,000 after purchasing an additional 32,065 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in shares of Pfizer by 3.5% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 89,833 shares of the biopharmaceutical company’s stock valued at $3,959,000 after purchasing an additional 3,029 shares in the last quarter. Price Capital Management Inc. acquired a new position in shares of Pfizer in the third quarter valued at $1,511,000. Finally, Mendel Money Management acquired a new position in shares of Pfizer in the third quarter valued at $657,000. Institutional investors and hedge funds own 69.17% of the company’s stock.

In other news, insider Mikael Dolsten sold 149,553 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $43.55, for a total value of $6,513,033.15. Following the completion of the sale, the insider now directly owns 390,097 shares in the company, valued at $16,988,724.35. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Pfizer Inc bought 50,000 shares of the stock in a transaction dated Monday, May 13th. The stock was acquired at an average price of $17.00 per share, with a total value of $850,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 288,726 shares of company stock valued at $12,534,617. 0.09% of the stock is currently owned by corporate insiders.

A number of research analysts recently commented on PFE shares. Bank of America upped their target price on Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 target price on shares of Pfizer in a research note on Tuesday, February 19th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research note on Thursday, January 31st. Credit Suisse Group reiterated a “buy” rating and set a $48.00 price objective on shares of Pfizer in a research note on Monday, May 6th. Finally, ValuEngine lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Fourteen research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $45.83.

Pfizer stock opened at $41.47 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27. Pfizer Inc. has a 52-week low of $35.32 and a 52-week high of $46.47. The firm has a market cap of $247.88 billion, a price-to-earnings ratio of 13.52, a P/E/G ratio of 2.41 and a beta of 0.71.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.10. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. The firm had revenue of $13.12 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same period in the prior year, the company posted $0.77 earnings per share. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.89 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 10th will be paid a $0.36 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.47%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

ILLEGAL ACTIVITY NOTICE: “Pfizer Inc. (PFE) Shares Bought by Oregon Public Employees Retirement Fund” was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/18/pfizer-inc-pfe-shares-bought-by-oregon-public-employees-retirement-fund.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Is a Roth IRA right for you?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.